Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

November 10th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC

November 9th 2018

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC

November 9th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non–small cell lung cancer (NSCLC).

Uncertainty Surrounds Nondriver NSCLC Treatment After Progression

November 9th 2018

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Drilon Sheds Light on Lesser-Known Markers in NSCLC

November 9th 2018

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Halmos Highlights Advances in Squamous NSCLC

November 7th 2018

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

Dr. West on FDA Approval of Lorlatinib in ALK+ NSCLC

November 3rd 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of lorlatinib for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC

November 3rd 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

FDA Approves Lorlatinib for ALK+ NSCLC

November 3rd 2018

The FDA has granted lorlatinib an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).

Nurses Play Pivotal Role in Patient Journey Through Lung Cancer Continuum

November 2nd 2018

Mary Pasquinelli, MS, APRN, discusses the pivotal role of nurses in lung cancer care.

Dr. Halmos on Second-Line Treatment in Metastatic Squamous NSCLC

November 2nd 2018

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses second-line treatment for patients with metastatic squamous non–small cell lung cancer (NSCLC).

Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC

October 31st 2018

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

October 31st 2018

The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.

Dr. Rudin Discusses the Success of Immunotherapy in SCLC

October 30th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

Dr. Borghaei on the Current Landscape of Immunotherapy in NSCLC

October 30th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the current landscape of immunotherapy in non–small cell lung cancer (NSCLC).

Thoracic Oncologist Highlights EGFR TKI Advances in NSCLC

October 30th 2018

Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.

Expert Discusses Durvalumab and Future of Immunotherapy in NSCLC

October 28th 2018

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC

October 25th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Role of Surgery in Early Lung Cancer Remains Invaluable

October 25th 2018

Mark Widmann, MD, discusses the role of surgery in the treatment of patients with early-stage lung cancer.